1. Home
  2. NX vs GHRS Comparison

NX vs GHRS Comparison

Compare NX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quanex Building Products Corporation

NX

Quanex Building Products Corporation

HOLD

Current Price

$17.68

Market Cap

852.1M

Sector

Industrials

ML Signal

HOLD

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$22.47

Market Cap

947.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NX
GHRS
Founded
1927
2018
Country
United States
Ireland
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
852.1M
947.2M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
NX
GHRS
Price
$17.68
$22.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$28.00
$41.38
AVG Volume (30 Days)
291.9K
193.7K
Earning Date
06-04-2026
05-01-2026
Dividend Yield
1.64%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,837,641,000.00
N/A
Revenue This Year
$4.26
N/A
Revenue Next Year
$1.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.81
N/A
52 Week Low
$11.04
$10.96
52 Week High
$22.90
$24.66

Technical Indicators

Market Signals
Indicator
NX
GHRS
Relative Strength Index (RSI) 42.10 61.36
Support Level $16.61 $12.65
Resistance Level $20.24 $22.88
Average True Range (ATR) 0.80 1.49
MACD -0.28 -0.13
Stochastic Oscillator 38.85 58.59

Price Performance

Historical Comparison
NX
GHRS

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: